Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
7 hedge funds and large institutions have $377K invested in Lipella Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
535% more capital invested
Capital invested by funds: $59.5K → $377K (+$318K)
75% more funds holding
Funds holding: 4 → 7 (+3)
5.69% more ownership
Funds ownership: 0.69% → 6.38% (+5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$314K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$49K |
| 3 |
Two Sigma Investments
New York
|
+$18.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.33K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$679 |
Top Sellers
LIPO Hedge Fund Activity: Q4 2023 in Review
7 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q4 2023, worth a combined $377K — up 535% from $59.5K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LIPO positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $314K.
- 7 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q4 2023, up from 4 in Q3 2023.
- Funds reported $377K of Lipella Pharmaceuticals stock for Q4 2023, up 535% quarter-over-quarter.
- 3 funds opened new Lipella Pharmaceuticals positions in Q4 2023 and 0 closed out, a net change of +3 holders.
- The largest Lipella Pharmaceuticals buyer in Q4 2023 was Sabby Management, an estimated $314K added.
Based on aggregated 13F filings for Q4 2023.